AbCellera Biologics Inc. financials

ABCL CIK 0001703057

Source: EDGAR filings · Built 2026-06-19T01:53:51Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Free Cash Flow -174.07M -186.95M -120.82M 206.70M 186.13M 13.02M
EBITDA -194.96M -287.93M -212.81M 244.35M 218.86M 160.87M
Working Capital 663.92M 674.76M 752.97M 907.17M 809.12M 709.84M
Net Debt 14.71M -90.96M -55.94M -304.28M -436.08M -589.54M
Operating Margin -288.98% -1091.69% -623.82% 44.60% 54.48% 66.92%
Net Margin -194.88% -564.83% -385.00% 32.66% 40.90% 51.00%
Return on Equity (ROE) -15.14% -15.42% -12.70% 12.85% 14.96% 14.32%
Return on Assets (ROA) -10.79% -11.97% -9.84% 10.29% 11.64% 11.83%
Current Ratio 11.32× 9.81× 7.33× 8.67× 7.70× 7.86×
Debt-to-Equity 0.15× 0.06× 0.07× 0.07× 0.04× 0.01×
Effective Tax Rate 17.56% 18.73% 15.88% 33.70% 29.97% 24.66%
Cash Conversion Ratio 0.90× 0.67× 0.30× 1.75× 1.59× 0.19×
Accruals Ratio -0.01× -0.04× -0.07× -0.08× -0.07× 0.10×
SBC % of Revenue 74.26% 234.39% 168.79% 10.19% 8.17% 3.60%
CapEx Coverage -3.07× -1.38× -0.57× 3.93× 4.18× 2.35×
Free Cash Flow Per Share $-0.58 $-0.64 $-0.42 $0.66 $0.58 $0.05

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Revenue from Contract with Customer, Excluding Assessed Tax 75.13M 28.83M 38.02M 485.42M 375.20M 233.16M
Research and Development Expense 186.83M 167.26M 175.66M 107.88M 62.06M 29.39M
Operating Expenses 292.23M 343.60M 275.23M 268.91M 170.79M 77.12M
Operating Income (Loss) -217.10M -314.77M -237.21M 216.51M 204.41M 156.03M
Income Tax Expense (Benefit) -31.18M -37.54M -27.63M 80.58M 65.69M 38.91M
Net Income (Loss) Attributable to Parent -146.41M -162.86M -146.40M 158.52M 153.46M 118.92M
Earnings Per Share, Basic $-0.49 $-0.55 $-0.51 $0.56 $0.56 $0.53
Weighted Average Number of Shares Outstanding, Basic 298.71M 294.33M 289.17M 285.06M 275.76M 159.20M
Earnings Per Share, Diluted $-0.49 $-0.55 $-0.51 $0.50 $0.48 $0.45
Weighted Average Number of Shares Outstanding, Diluted 298.71M 294.33M 289.17M 314.83M 318.29M 263.13M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Cash and Cash Equivalents, at Carrying Value 61.80M 55.60M 52.20M 44.90M 8.20M 900.00K
Assets, Current 728.23M 751.37M 871.99M 1.03B 929.80M 813.33M
Assets 1.36B 1.36B 1.49B 1.54B 1.32B 1.01B
Liabilities, Current 64.31M 76.61M 119.01M 118.32M 120.68M 103.49M
Liabilities 390.05M 304.47M 335.78M 307.63M 292.84M 175.03M
Stockholders' Equity Attributable to Parent 966.90M 1.06B 1.15B 1.23B 1.03B 830.51M
Common Stock, Shares, Outstanding 300.60M 295.76M 290.82M 286.85M 283.26M 269.50M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Net Cash Provided by (Used in) Operating Activities -131.29M -108.56M -43.88M 277.36M 244.58M 22.69M
Payments to Acquire Property, Plant, and Equipment 42.77M 78.40M 76.95M 70.66M 58.45M 9.67M
Net Cash Provided by (Used in) Investing Activities 87.75M 121.41M -221.11M -352.63M -332.25M -119.78M
Net Cash Provided by (Used in) Financing Activities 14.08M 12.77M 10.36M -1.63M -3.89M 683.65M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ABCL CIK 0001703057), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

WTFCN

WINTRUST FINANCIAL CORP

ESLAW

ESTRELLA IMMUNOPHARMA, INC.

NUTR

NusaTrip Incorporated